Search for: "Watson v. Mylan Pharmaceuticals"
Results 1 - 20
of 62
Sorted by Relevance
|
Sort by Date
8 Jan 2012, 9:05 pm
Takeda Pharmaceutical Co. et al. v. [read post]
15 Sep 2013, 9:42 pm
• Defendant: Mylan Pharmaceuticals Inc. [read post]
6 Apr 2017, 1:35 pm
See Medicines Co. v. [read post]
10 Mar 2013, 9:59 pm
Searle LLC; Pfizer Asia Pacific PTE, LTD.; • Defendants: Lupin Pharmaceuticals, Inc.; Teva Pharmaceuticals USA, Inc.; Mylan Pharmaceuticals Inc.; Watson Laboratories, Inc.; Apotex Inc.; Apotex Corp. [read post]
17 Feb 2010, 8:00 am
Mylan Pharmaceuticals Inc. [read post]
18 Dec 2009, 9:59 am
Watson Laboratories, Inc.- Florida, Watson Pharma Inc. and Watson Pharmaceuticals Inc. [read post]
25 Aug 2014, 8:57 am
Some district courts have permitted originators to maintain declaratory actions against a generic manufacturer (see e.g. the Second Circuit in Cephalon v Watson (2009)). [read post]
17 Mar 2014, 11:03 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited (these three companies are, collectively, "Mylan"); Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco… [read post]
17 Jul 2014, 10:58 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.; Sun Pharma Global Inc.;… [read post]
30 Jun 2014, 10:28 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.; Sun Pharma Global Inc.;… [read post]
25 Mar 2011, 8:29 pm
" Duramed Pharmaceuticals v. [read post]
26 Feb 2014, 5:37 pm
Procedural HistoryPlaintiff GlaxoSmithKline LLC (“GSK”) sued Banner Pharmacaps, Inc., Impax Laboratories, Inc., Roxane Laboratories, Inc., Mylan Inc., Mylan Pharmaceuticals, Inc., and Watson Laboratories, Inc. [read post]
5 May 2010, 4:46 am
Mylan Pharmaceuticals Inc. et al. [read post]
29 Mar 2011, 9:19 pm
Merck (Kluwer Patent Blog) Keppra (Levetiracetam) – US: Orange Book patent listing precipitates DJ action to trigger generic Keppra XR 180-day exclusivity forfeiture: Par Pharmaceutical v UCB et al (FDA Law Blog) (Patent Docs) Naropin (Ropivacaine) – US: Judge O’Malley in dissent: Patent assignments should be a matter of state law: Abraxis BioScience v. [read post]
26 May 2007, 11:26 pm
On Sunday, May 27, 2007, the Newark Star-Ledger got around to observing that KSR v. [read post]
12 Oct 2010, 8:56 pm
Highlights this week included: Aricept(Donepezil) –US: Declaratory judgment jurisdiction for subsequent Paragraph IV filers: Teva Pharmaceuticals USA, Inc. v. [read post]
14 Nov 2016, 9:16 am
Kraft Food Brands Group LLC, No 16-341 (Does the general and broad definition of “residence” found in 28 U.S.C. 1391(c) apply to the patent venue statute 1400(b)) Civil Procedure – Personal Jurisdiction: Mylan Pharmaceuticals, et al. v. [read post]
3 Nov 2010, 1:21 am
No – discussion of patent-eligibility standards for genes (Patent Baristas) US: Appellees file reply brief in Therasense v Becton Dickinson (Patent Docs) US: Another Capitol Hill missive objects to the inclusion of patent settlement provisions in FY 2011 Appropriations Bill (FDA Law Blog) US: REMS and 180-day exclusivity forfeiture – some interesting disclosures to the SEC (FDA Law Blog) Products Botox (Botulinum) – EU: General Court upholds opposition to BOTUMAX Community… [read post]
15 Aug 2012, 11:02 am
According to Watson, “[b]ased on the simultaneous filing of the Watson ANDA with Mylan and Ranbaxy’s ANDAs, Watson has expected to share the period of 180-day exclusivity with Mylan and Ranbaxy (as well as with a fourth generic manufacturer, Teva Pharmaceuticals (‘Teva’), that has been granted a license by Takeda). [read post]
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based… [read post]
